Shots:

• The P-III TIVO-3 study involves assessing of Fotivda (tivozanib) vs sorafenib in 350 patients with refractory advanced or metastatic renal cell carcinoma (RCC)
• P-III TIVO-3 results: 44% improvement in mPFS; 26% reduction in the risk of progression or death; mPFS (5.6 vs 3.9 mos.); ORR (18% vs 8%)- presented at ASCO Genitourinary Cancers Symposium- 2019
• FOTIVDA (tivozanib- qd- PO) is a VEGF tyrosine kinase inhibitor (TKI) targeted & approved in EU for RCC and is evaluated in P-II in combination with nivolumab (anti PD-1) for RCC

Ref: AVEO Oncology | Image: Pharma Journalist